<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>6 November 2013</title></head><body><div><p style="margin:0pt"><span style="color:#191919; font-family:Calibri; font-size:11pt">&#xa0;</span></p><h1 style="line-height:24pt; margin:0pt 0pt 12pt 28.35pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Society for General Microbiology </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">(AMR0040)</span></h1><p style="line-height:16pt; margin:0pt 0pt 3pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-variant:small-caps">Introduction</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">The Society for General Microbiology (SGM) is a membership organisation for scientists who work in all areas of microbiology. It is the largest learned microbiological society in Europe with a worldwide membership based in universities, industry, hospitals, research institutes and schools. The SGM publishes key academic journals in microbiology and virology, organises international scientific conferences and provides an international forum for communication among microbiologists and supports their professional development. The Society promotes the understanding of microbiology to a diverse range of stakeholders, including policy-makers, students, teachers, journalists and the wider public, through a comprehensive framework of communication activities and resources. Further information about SGM is provided in Appendix 1.</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">&#xa0;</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">The prevalence of antibiotic resistance should not surprise us. The problem is an inevitable consequence of human behaviour, evolutionary pressures and the ability of micro-organisms to rapidly change their genetic makeup. Despite this we believe that the scientific community – and broader society – is ingenious and determined enough to discover solutions that overcome the problems of antimicrobial resistance.</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">Our emphasis in this consultation response is on the need for greater capacity in the basic research required to fight infection. Quite rightly basic research is proposed in the government’s </span><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt; font-style:italic">UK Five Year Antimicrobial Resistance Strategy,</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">as part of the overall solution to antibiotic resistance but details about how the research will be delivered were scarce. Basic research is, in our view, the only means of finding long-term solutions to the threat of antimicrobial resistance.</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 0pt 3pt 28.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-variant:small-caps; font-weight:normal">1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps; font-weight:normal">How has antimicrobial resistance developed in the past decade?</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">It is certain that micro-organisms can develop resistance to antimicrobial drugs; beyond this general statement, a more complex picture emerges in which some infections, notably, methicillin-resistant </span><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt; font-style:italic">Staphylococcus aureus</span><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt"> (MRSA) and HIV show, respectively, declining and stable levels of resistance, while others, notably tuberculosis, register increases.</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt"> For a third, and very large group of infections, we have little or no data on resistance patterns: surveillance in these infections is not carried out. Treatment failure may be occurring, but neither it, nor antimicrobial resistance, is being </span><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">systematically reported.</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt"> The most serious disease threats are from chronic infections including multidrug resistant tuberculosis, Gram-negative infections and hospital-acquired infections.</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 0pt 3pt 28.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-variant:small-caps; font-weight:normal">2.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps; font-weight:normal">What are the gaps in our knowledge about antimicrobial resistance?</span></p><p style="line-height:16pt; margin:0pt 0pt 0pt 56.7pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">2.1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">Diagnosis of antimicrobial resistance and routine surveillance of resistance rates</span></p><ul type="square" style="margin:0pt; padding-left:0pt"><ul type="square" style="margin:0pt; padding-left:0pt"><ul type="square" style="margin:0pt; padding-left:0pt"><li style="color:#191919; font-family:Wingdings; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 78.78pt; padding-left:7.97pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">Outside of a small number of infections, e.g., tuberculosis, we lack systematic data on the rates of antimicrobial resistance, both in the UK and overseas. The lack of data is due to an absence of inexpensive, standardised tests, and/or the fact that certain infections are not on policy-makers’ ‘radar’. Systematic data could, if collected, inform the focus of research, assist us in identifying the most urgent problems, and allow us to horizon scan.</span></li><li style="color:#191919; font-family:Wingdings; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 78.78pt; padding-left:7.97pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">We have insufficient understanding of the evolution and spread of resistance. We have insufficient data </span><a name="_GoBack"></a><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">on the use of combination therapies, co-drugs, and adjuvants that could increase or extend the performance of existing therapies. </span></li><li style="color:#191919; font-family:Wingdings; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 78.78pt; padding-left:7.97pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">We lack rapid diagnostic tests for resistance in some organisms, notably, sexually-transmitted infections such as gonorrhoea. Such diagnostic tests would allow physicians to prescribe the most effective, tailored, treatments, and will contribute significantly to antibiotic stewardship (i.e., the right antibiotic for the right infection). Developments in genomics will be vital in this area. There is also a need for operational research to introduce new tests into the health service.</span></li><li style="color:#191919; font-family:Wingdings; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 78.78pt; padding-left:7.97pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">We should encourage basic scientific research in areas relevant to resistance, e.g., studies of the mechanisms of emergence of resistant bacteria, drug discovery including natural products research, studies of the ecology of infection and the microbiome, infection diagnostics, vaccines, and immune responses to infection. </span></li></ul></ul></ul><p style="line-height:16pt; margin:0pt 0pt 0pt 56.7pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">2.2.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">Expanding the working life of existing antimicrobial treatments and developing new ones</span></p><ul type="square" style="margin:0pt; padding-left:0pt"><ul type="square" style="margin:0pt; padding-left:0pt"><ul type="square" style="margin:0pt; padding-left:0pt"><li style="color:#191919; font-family:Wingdings; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 78.78pt; padding-left:7.97pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">Antimicrobial resistance is an inevitable process; therefore, we need to ensure the drug development pipeline is adequately stocked. Currently, there is an urgent need to focus drug development on treatments against infections due to Gram-negative bacteria, particularly those resistant to carbapenems; antibiotics suitable for paediatric use; drugs to fight methicillin- and vancomycin-resistant </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:italic">Staphylococcus</span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt"> strains; and fungal infections (</span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:italic">Candida</span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt"> and aspergillosis).</span></li><li style="color:#191919; font-family:Wingdings; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 78.78pt; padding-left:7.97pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">We need greater understanding at the fundamental level of tried and tested antibiotic drug targets. These include how the bacterial cell wall is assembled, and how bacterial proteins are synthesised, and other essential processes both in model organisms and pathogens.</span></li><li style="color:#191919; font-family:Wingdings; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 78.78pt; padding-left:7.97pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">Many drugs, especially in Gram-negative bacteria are not able to reach their targets due to membrane barriers. We need a more comprehensive understanding </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">of how chemicals move in and out of bacterial cells. Studies on how to design compounds, adjuvants, and co-drugs to facilitate movement into cells should be encouraged.</span></li><li style="color:#191919; font-family:Wingdings; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 78.78pt; padding-left:7.97pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">We need to focus attention on the problems of treating chronic and persistent infections (e.g., non-healing wounds, implanted device-associated infection, and cystic fibrosis respiratory infections). Currently, the research emphasis is often on acute infections – yet persistent infections require long-term antimicrobial treatment, thus contributing to the development of resistance. It is worth noting a recent initiative in the USA that targets research on chronic and persistent infections.</span><a name="_ftnref4"></a><a href="#_ftn4">[4]</a></li><li style="color:#191919; font-family:Wingdings; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 78.78pt; padding-left:7.97pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">We need to focus a part of our efforts on screening plants and soil micro-organisms for natural products that could be used as drugs. The soil in particular has been the most productive niche to date for antibiotic discovery, and we should encourage research on particular bacterial taxa with known tendencies to make antibiotics, notably, </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:italic">Streptomyces</span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">. We need to reinforce expertise in microbial physiology, microbial culture techniques, taxonomy and ecology as well as invest in rapid high throughput robotic screening techniques.</span></li></ul></ul></ul><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 0pt 3pt 28.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-variant:small-caps; font-weight:normal">3.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps; font-weight:normal">Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified?</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">Risk-sharing via an international partnership appears to be the most common current means of stimulating antibiotic drug discovery. The major public-private partnership is the EU’s €223.7 million Innovative Medicines Initiative ‘Combating Antibiotic Resistance: New Drugs for Bad Bugs (ND4BB)’.</span><a name="_ftnref5"></a><a href="#_ftn5">[5]</a><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt"> We should ensure the UK is contributing to, and benefiting from, all relevant international schemes. </span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">In the UK, private-sector antibacterial drug development is now primarily located in small pharmaceutical and biotech companies. We see evidence for a dynamic and innovative sector with more than 20 active firms across the UK – as we noted in a previous consultation response to the Science and Technology Committee.</span><a name="_ftnref6"></a><a href="#_ftn6">[6]</a><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt"> The EU’s Innovative Medicines Initiative, while often seen as the solution, is little help to this vital sector. Funders should therefore investigate what strategies we have in place currently, or could put in place, to support antimicrobial drug discovery in relevant UK firms, and promote fruitful interaction with the wealth of knowledge and skills in academia. For example, it may be useful to consider if a concentration of firms and researchers in one or more centres would encourage innovation.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">There is a need to encourage partnerships between academia and industry, and to incentivise firms to develop new antimicrobial treatments. The Wellcome Trust, for example, has a Seeding Drug Discovery initiative; the MRC has MRC Technology. </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">Various forms of industry incentivisation (both push, and pull) need to be investigated, and those proven most effective should be implemented, particularly those measures that de-risk and unlock private sector investment (e.g., early-stage funding for proof of concept, pre-clinical work and toxicity testing). Industry is not going to take the initiative on its own.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">Research spending on antibiotic resistance from public funds appears to have been low. In the years 1997-2010, research on antibiotic resistance is reported to have received only 3.9% of total UK public-sector spending on infectious disease research.</span><a name="_ftnref7"></a><a href="#_ftn7">[7]</a><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt"> The exact nature, causes, and effects, of this reported underfunding on the early-stage pipeline in antimicrobial therapies warrant investigation.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">We encourage projects shared between the Research Councils, Technology Strategy Board, and the National Institute for Health Research. Interactions should be built around a clear goal, and involve basic research, social science, and engagement with clinical and industrial fields. Interaction between academic researchers and clinicians should be encouraged for proof-of-concept studies that will draw buy-in from the private sector. We should explore roles for learned societies in promoting cross-working. </span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">Seek to interest microbiologists at all levels of academia and industry in the problems of antibiotic resistance and antimicrobial drug discovery. There has been a dwindling of interest academically in this type of research, exacerbated or even led by declining interest from Big Pharma. We should seek to train and interest graduates in this area by emphasising the life-saving nature of antibiotics and how they underpin modern medicine.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">Identify factors contributing to successful antibiotic drug discovery in the past and present, and what we might learn for the design of new programmes. This will require research by social scientists.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">Many organisations are conducting vital work examining the crisis in antimicrobial drugs, and seeking policy solutions. These include the European Commission; the UK’s health, and environment, food and rural affairs departments; government bodies and learned societies overseas, such as the German Academies of Science; learned societies in the UK (e.g., SGM), think-tanks; research funders, notably the Wellcome Trust; and researcher networks and forums, e.g., the Infectious Diseases Research Network (IDRN).</span><a name="_ftnref8"></a><a href="#_ftn8">[8]</a><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt"> These initiatives are valuable and should be encouraged, and could be linked via a ‘Round Table’ or forum, as has been suggested in Germany.</span><a name="_ftnref9"></a><a href="#_ftn9">[9]</a></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">Recommendations emerged from a one-day meeting at the Wellcome Trust in May, including a call for the formation of cross-sector consortia, and a renewed role for the public sector; these should be explored.</span><a name="_ftnref10"></a><a href="#_ftn10">[10]</a></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">Chemists and modellers have a vital role devising new antibiotics based on fundamental microbiological research. The UK has great scientific strength </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">across academia, the research institutes, and the private sector (particularly start-ups and small and medium-sized enterprises), but i</span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">nterdisciplinary working will be critical and is something SGM actively seeks to promote.</span></li></ul><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 0pt 3pt 28.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-variant:small-caps; font-weight:normal">4.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps; font-weight:normal">What measures (including behavioural change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens?</span></p><p style="line-height:16pt; margin:0pt; text-align:justify; text-indent:28.35pt"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">No comment.</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 0pt 3pt 28.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-variant:small-caps; font-weight:normal">5.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps; font-weight:normal">What global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?</span></p><p style="line-height:16pt; margin:0pt; text-align:justify; text-indent:28.35pt"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">No comment.</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 0pt 3pt 28.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-variant:small-caps; font-weight:normal">6.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps; font-weight:normal">What are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">Quite rightly basic research is proposed in the government’s </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:italic">UK Five Year Antimicrobial Resistance Strategy,</span><a name="_ftnref11"></a><a href="#_ftn11">[11]</a><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">as</span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">part of the overall solution to antibiotic resistance but details about how the research will be delivered are scarce.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">The SGM, in collaboration with other learned societies, is therefore pressing for a coherent strategic plan for research fighting infectious disease, including tackling the challenge of antimicrobial resistance.</span><a name="_ftnref12"></a><a href="#_ftn12">[12]</a></li></ul><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Society for General Microbiology – Chair of the Policy Committee:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">Professor Maggie Smith, University of York</span></li></ul><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">&#xa0;</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Society for General Microbiology – Policy Committee:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">Professor Nigel Brown, Emeritus Professor, University of Edinburgh</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">Professor Martin Cranage, St George’s, University of London</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">Dr Pat Goodwin, Consultant, C3 Collaborating for Health</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">Professor Colin Harwood, Newcastle University</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">Mr Scott Nicholson, University of the West of Scotland</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">Professor Gill Stephens, University of Nottingham</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">Dr Jeremy Webb, University of Southampton</span></li></ul><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">&#xa0;</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">The Policy Committee additionally sought information from Dr Mike Dawson (Novacta Biosystems Ltd), Professor David Denning (University Hospital of South Manchester), Professor David Dunn (MRC Clinical Trials Unit), Dr Malcolm Rhodes (University of Manchester), Professor Jodi Lindsay (St George’s University of London), and Professor David Livermore (Lead, Antibiotic Resistance, Public Health England) in preparing this response.</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">&#xa0;</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:normal">November 2013</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="color:#262626; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">&#xa0;</span></p><h3 style="line-height:17pt; margin:0pt 0pt 3pt 28.35pt; page-break-after:avoid; page-break-inside:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:bold">Appendix 1: The Society for General Microbiology</span></h3><h4 style="line-height:16pt; margin:0pt 0pt 3pt 28.35pt; page-break-after:avoid; page-break-inside:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:bold">Vision</span></h4><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">A world in which the science of microbiology provides maximum benefit to society.</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">&#xa0;</span></p><h4 style="line-height:16pt; margin:0pt 0pt 3pt 28.35pt; page-break-after:avoid; page-break-inside:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:bold">Mission</span></h4><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">To promote high-quality microbiological science, both nationally and internationally, to a diverse range of stakeholders.</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">&#xa0;</span></p><h4 style="line-height:16pt; margin:0pt 0pt 3pt 28.35pt; page-break-after:avoid; page-break-inside:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:bold">Rationale</span></h4><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">The potential socio-economic benefits arising from microbiology are substantial. They include:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">A healthier future (for humans, animals and plants) and a better quality of life, within the context of a sustainable natural environment.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">The development of biotechnology products (such as food, drinks, biopesticides, biofuels and medicines), which generate wealth and employment, and so support growth and innovation.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">The advancement of scientific knowledge, as a benefit in its own right, and to allow us to plan for the future and contribute to international solutions for global challenges, such as climate change, the burden of disease and food security.</span></li></ul><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">&#xa0;</span></p><h4 style="line-height:16pt; margin:0pt 0pt 3pt 28.35pt; page-break-after:avoid; page-break-inside:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:bold">Strategic priorities</span></h4><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">To achieve its Vision and Mission, the Society will work towards the strategic priorities below.</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">Publishing: to contribute to the science of microbiology through high-quality publications.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">Scientific conferences: to hold international scientific conferences to disseminate research knowledge and provide a forum for communication between microbiologists and to grow and support communities among them.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">Raising awareness: to inspire and educate people about microbiology, and allow them to make informed decisions which recognize the importance of microbiology and its advances.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">Influencing policy: to ensure that appropriate scientific information and expert opinion are made available to policy- and decision-makers and that the improvement of resources and infrastructure for microbiology is supported.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:16pt; margin:0pt 0pt 0pt 38.41pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">Professional development: to promote microbiology as a career from school level onwards and support career and professional development of microbiologists.</span></li></ul><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">&#xa0;</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">The Society is a Charity registered in England and Wales (No. 264017) and in Scotland (No.</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">SC039250) and a Company Limited by Guarantee, registered in England and Wales (No.</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">1039582).</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal">&#xa0;</span></p><p style="line-height:16pt; margin:0pt; text-align:justify"><span style="color:#191919; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 18pt 0pt 0pt"><span style="color:#191919; font-family:Calibri; font-size:11pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><span style="color:#191919; font-family:Calibri; font-size:10pt">Depar</span><span style="color:#191919; font-family:Calibri; font-size:10pt">tment of Health/</span><span style="color:#191919; font-family:Calibri; font-size:10pt">Department for the Environment, Food and Rural Affairs</span><span style="color:#191919; font-family:Calibri; font-size:10pt">,</span><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">UK Five Year Antimicrobial Resistance Strategy 2013 to 2018</span><span style="color:#191919; font-family:Calibri; font-size:10pt">; </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf</span></a><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span></p><p style="margin:0pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-weight:bold">Alan P. Johnson, John Davies, Rebecca Guy, Julia Abernethy, Elizabeth Sheridan, Andrew Pearson and Georgia Duckworth (2012).</span><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><span style="color:#191919; font-family:Calibri; font-size:10pt">Mandatory surveillance of methicillin-resistant </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">Staphylococcus aureus</span><span style="color:#191919; font-family:Calibri; font-size:10pt"> (MRSA) bacteraemia</span><span style="color:#191919; font-family:Calibri; font-size:10pt"> in England: the first 10 years. </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">Journal of Antimicrobial Chemotherapy,</span><span style="color:#191919; font-family:Calibri; font-size:10pt"> doi: 10.1093/jac/dkr561 (Figure 1); </span><a href="http://jac.oxfordjournals.org/content/67/4/802.full"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://jac.oxfordjournals.org/content/67/4/802.full</span></a><span style="color:#191919; font-family:Calibri; font-size:10pt">. </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-weight:bold">UK Collaborative Group on HIV Drug Resistance (2012).</span><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><span style="color:#191919; font-family:Calibri; font-size:10pt">Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">British Medical Journal,</span><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><span style="color:#191919; font-family:Calibri; font-size:10pt">doi: 10.1136/bmj.e5253</span><span style="color:#191919; font-family:Calibri; font-size:10pt">, </span><a href="http://www.bmj.com/content/345/bmj.e5253"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://www.bmj.com/content/345/bmj.e5253</span></a><span style="color:#191919; font-family:Calibri; font-size:10pt">. Public Health England, July 2013, ‘</span><span style="color:#191919; font-family:Calibri; font-size:10pt">Number and proportion of tuberculosis cases with first line drug</span><span style="color:#191919; font-family:Calibri; font-size:10pt"> resistance, UK, 2000-2012’; </span><a href="http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139697461"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139697461</span></a><span style="color:#191919; font-family:Calibri; font-size:10pt">.</span></p><p style="margin:0pt"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="color:#191919; font-family:Calibri; font-size:10pt"> To the best of our knowledge, no comprehensive account of UK resistance rates has been published since 2007; </span><a href="http://www.hpa.org.uk/Publications/InfectiousDiseases/AntimicrobialAndHealthcareAssociatedInfections/0712Antimicrobialresistance/"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">www.hpa.org.uk/Publications/InfectiousDiseases/AntimicrobialAndHealthcareAssociatedInfections/0712Antimicrobialresistance/</span></a><span style="color:#191919; font-family:Calibri; font-size:10pt">.</span></p><p style="margin:0pt"><a name="_ftn4"></a><a href="#_ftnref4">[4]</a><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><a href="http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-020.html"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-020.html</span></a></p><p style="margin:0pt"><a name="_ftn5"></a><a href="#_ftnref5">[5]</a><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><a href="http://blogs.nature.com/news/2012/05/europe-targets-superbugs-with-public-private-effort.html"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://blogs.nature.com/news/2012/05/europe-targets-superbugs-with-public-private-effort.html</span></a><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span></p><p style="margin:0pt"><a name="_ftn6"></a><a href="#_ftnref6">[6]</a><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><span style="color:#191919; font-family:Calibri; font-size:10pt">Society for General Microbiology Consultation Response</span><span style="color:#191919; font-family:Calibri; font-size:10pt">:</span><span style="color:#191919; font-family:Calibri; font-size:10pt"> Research and Development funding for science and technology in the UK</span><span style="color:#191919; font-family:Calibri; font-size:10pt">, 28 August 2013. Please contact SGM for a list of firms.</span></p><p style="margin:0pt"><a name="_ftn7"></a><a href="#_ftnref7">[7]</a><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-weight:bold">Michael G. Head, Joseph R. Fitchett, Mary K. Cooke, Fatima B. Wurie, Rifat Atun, Andrew C. Hayward, Alison Holmes, Alan P. Johnson, and Neil Woodford (2013). </span><span style="color:#191919; font-family:Calibri; font-size:10pt">Systematic analysis of funding awarded for antimicrobial resistance research to institutions in the UK, 1997-2010. </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">Journal of Antimicrobial Chemotherapy,</span><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><span style="color:#191919; font-family:Calibri; font-size:10pt">doi: 10.1093/jac/dkt349</span><span style="color:#191919; font-family:Calibri; font-size:10pt">, </span><a href="http://jac.oxfordjournals.org/content/early/2013/09/13/jac.dkt349.full"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://jac.oxfordjournals.org/content/early/2013/09/13/jac.dkt349.full</span></a><span style="color:#191919; font-family:Calibri; font-size:10pt">. </span><span style="color:#191919; font-family:Calibri; font-size:10pt">A word cloud available online shows this funding </span><span style="color:#191919; font-family:Calibri; font-size:10pt">shortfall</span><span style="color:#191919; font-family:Calibri; font-size:10pt"> graphically</span><span style="color:#191919; font-family:Calibri; font-size:10pt"> - </span><a href="http://www.researchinvestments.org/"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://www.researchinvestments.org/</span></a><span style="color:#191919; font-family:Calibri; font-size:10pt">. These data run until 2010 only; later data are not yet available.</span></p><p style="margin:0pt"><a name="_ftn8"></a><a href="#_ftnref8">[8]</a><span style="color:#191919; font-family:Calibri; font-size:10pt"> SGM can supply a full list of the initiatives we are aware about – please contact us. SGM currently collaborates with other learned societies on antimicrobial resistance; these include the Biochemical Society, British Society for Antimicrobial Chemotherapy, Royal Society of Chemistry, Society for Applied Microbiology and Society of Biology.</span></p><p style="margin:0pt"><a name="_ftn9"></a><a href="#_ftnref9">[9]</a><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-weight:bold">Academy of Sciences and Humanities in Hamburg/German National Academy of Sciences Leopoldina (2013</span><span style="color:#191919; font-family:Calibri; font-size:10pt">). </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">Antibiotics Research: Problems </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">and Perspectives</span><span style="color:#191919; font-family:Calibri; font-size:10pt">, p. 10; </span><a href="http://www.leopoldina.org/uploads/tx_leopublication/2013_06_17_Antibiotics_Research.pdf"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://www.leopoldina.org/uploads/tx_leopublication/2013_06_17_Antibiotics_Research.pdf</span></a><span style="color:#191919; font-family:Calibri; font-size:10pt">. </span></p><p style="margin:0pt"><a name="_ftn10"></a><a href="#_ftnref10">[10]</a><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-weight:bold">Antibiotic Action (2013). </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">Lessons to be </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">learnt from P</span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">harma</span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic"> about D</span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">iscovery and </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">D</span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">evelopment </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">of N</span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">ew </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">A</span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">ntibacterial </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">D</span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">rugs,</span><span style="color:#191919; font-family:Calibri; font-size:10pt"> p. 3; </span><a href="http://antibiotic-action.com/wp-content/uploads/2013/08/Learning-Lessons-report.pdf"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://antibiotic-action.com/wp-content/uploads/2013/08/Learning-Lessons-report.pdf</span></a><span style="color:#191919; font-family:Calibri; font-size:10pt">. </span></p><p style="margin:0pt"><a name="_ftn11"></a><a href="#_ftnref11">[11]</a><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><span style="color:#191919; font-family:Calibri; font-size:10pt">Depar</span><span style="color:#191919; font-family:Calibri; font-size:10pt">tment of Health/</span><span style="color:#191919; font-family:Calibri; font-size:10pt">Department for the Environment, Food and Rural Affairs</span><span style="color:#191919; font-family:Calibri; font-size:10pt">,</span><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span><span style="color:#191919; font-family:Calibri; font-size:10pt; font-style:italic">UK Five Year Antimicrobial Resistance Strategy 2013 to 2018</span><span style="color:#191919; font-family:Calibri; font-size:10pt">; </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf</span></a><span style="color:#191919; font-family:Calibri; font-size:10pt"> </span></p><p style="margin:0pt"><a name="_ftn12"></a><a href="#_ftnref12">[12]</a><span style="color:#191919; font-family:Calibri; font-size:10pt"> For a programmatic statement of SGM’s current policy approach, please see: </span><span style="color:#191919; font-family:Calibri; font-size:10pt">Society for General Microbiology </span><span style="color:#191919; font-family:Calibri; font-size:10pt">Policy Note: Antimicrobial Resistance Policy, 7 June 2013; </span><a href="http://www.sgm.ac.uk/en/policy/consultation-responses.cfm"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://www.sgm.ac.uk/en/policy/consultation-responses.cfm</span></a><span style="color:#191919; font-family:Calibri; font-size:10pt">. </span></p></body></html>